For the present study, the group of cancer testis antigens (CTA's) are of special interest, since expression of these are known to be regulated by methylation, and therefore affected by hypo-methylating treatment such as azacitidine. CTA's are known to be immunogenic and are only expressed at immunoprivileged sites, thus out of reach of immune responses, and on cancer cells, making them ideal targets for therapeutic cancer vaccination.